Fundraising Fox

Abcuro

Newton, US · Delaware corporation · 9 known investors

abcuro.com ↗

Abcuro is a clinical-stage biopharmaceutical company developing ulviprubart, a monoclonal antibody that selectively depletes highly cytotoxic T cells by targeting the KLRG1 receptor. Its lead candidate is being developed for autoimmune disorders and rare cancers, including inclusion body myositis, T-cell large granular lymphocytic leukemia, and T and NK cell lymphomas.

BiotechHealthtech

Founders & leadership

JA
John Alexander MartinExecutive Officer, Director
SG
Stefano GullaExecutive Officer
RB
Ryan BerryDirector
DM
Donald McCarthyDirector
JE
John EdwardsDirector
YX
Yajun XuDirector
JK
Julius KnowlesDirector
ET
Evan ThompsonExecutive Officer
DD
David de GraafExecutive Officer, Director
IR
Iyona RajkomarDirector
SA
Steven A. GreenbergChief Scientific Advisor & Co-Founder
AM
Alex MartinChief Executive Officer

Investors · 9

Bain Capital Life Sciences✓ verifiedBoston
RA Capital✓ verifiedBoston
Samsara BioCapital✓ verifiedPalo Alto
Sanofi Ventures✓ verifiedCambridge · $5Mvia Jason P. Hafler · board
Mass General Brigham Ventures✓ verifiedBoston
New Enterprise Associates (NEA)✓ verifiedMenlo Park · $200K – $40M
REDMILE✓ verifiedSan Francisco
Pontifax Venture CapitalHerzeliya · $6.3M – $128Mvia Tomer Kariv · board
ShangBay Capital LLCPalo Alto

Reported raises · per SEC filings

Form D private placements
▶$80MraisedFeb 2025 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John Alexander MartinExecutive Officer, Director
  • Sarah BoyceDirector
  • Michele ParkDirector
  • Mark PruzanskiDirector
  • Jason HaflerDirector
  • Rajeev ShahDirector
  • Ming FangDirector
  • Michael DybbsDirector
Offering amount
$200M
Amount sold
$80M
First sale
Feb 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$120.1MraisedAug 2023 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Julius KnowlesDirector
  • Donald McCarthyDirector
  • Rajeev ShahDirector
  • John Alexander MartinExecutive Officer, Director
  • Tomer KarivDirector
  • Jason HaflerDirector
  • Richard MotschwillerExecutive Officer
  • Darlene Deptula-HicksDirector
Offering amount
$199.5M
Amount sold
$120.1M
First sale
Aug 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.5MraisedJan 2021 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stefano GullaExecutive Officer
  • Jason HaflerDirector
  • Ryan BerryDirector
  • Donald McCarthyDirector
  • John EdwardsDirector
  • Yajun XuDirector
  • Julius KnowlesDirector
  • Evan ThompsonExecutive Officer
  • David de GraafExecutive Officer, Director
  • Iyona RajkomarDirector
Offering amount
$42M
Amount sold
$15.5M
First sale
Jun 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8MraisedNov 2018 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • K. Evan ThompsonExecutive Officer, Director
  • Robert MillmanDirector
  • Yajun XuDirector
  • Stefano GullaExecutive Officer, Director
  • Julius KnowlesDirector
  • Nalan UtkuDirector
Offering amount
$8M
Amount sold
$8M
Proceeds to insiders
$880K
First sale
Nov 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.3MraisedDec 2016 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Yajun XuDirector
  • Julius KnowlesDirector
  • Stefano GullaExecutive Officer, Director
  • K. Evan ThompsonExecutive Officer, Director
Offering amount
$2.3M
Amount sold
$2.3M
Proceeds to insiders
$500K
First sale
Nov 2016
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.